The New Masimo Patient SafetyNet and the Innovative, Upgradable Masimo Rainbow
SET Technology Platform Will Help Clinicians Meet Standards Bodies' Calls to Improve Patient Safety
IRVINE, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion
pulse oximetry, today announced it will launch Masimo Patient SafetyNet, a new
remote monitoring and clinician notification system, and showcase its
upgradable Masimo Rainbow SET technology platform at the 2007 American Society
of Anesthesiologists (ASA) Annual Meeting in San Francisco, California on
October 13, 2007.
Masimo Patient SafetyNet is an easy-to-use system that combines the "gold
standard" performance of Masimo SET pulse oximetry with wireless clinician
notification via pager to provide a new level of safety to patients on general
care floors, where nurse-to-patient ratios preclude the level of direct
surveillance required and recommended to preempt sentinel events. Numerous
standards bodies, including the Joint Commission (JCAHO), the American Society
of Anesthesiologists, the Anesthesia Patient Safety Foundation and the
Institute for Healthcare Improvement are calling for improved patient safety
standards on general care floors.
Masimo Patient SafetyNet is specifically designed to keep at-risk patients
safe on general care floors by connecting them to qualified caregivers
quickly, easily, and accurately. When a Patient SafetyNet-monitored patient is
in respiratory distress, meaningful and actionable alarms are generated by the
Masimo bedside monitor and sent wirelessly to designated clinicians for review
and response. As a result, appropriate clinical intervention can be initiated
quickly, preempting sentinel events -- defined by the Joint Commission as "an
unexpected occurrence involving death or serious physical injury not related
to the natural course of the patient's illness."
The Masimo Patient SafetyNet system instantly routes bedside-generated
alarms through a server to a qualified clinician's hand-held paging device in
real-time. For added safety, the system allows for automatic escalation of the
alarm to additional clinicians when necessary. Each Masimo Patient SafetyNet
system can support up to 40 bedside monitors and can either be integrated into
a hospital's existing IT infrastructure or operate as a stand-alone wireless
network.
The Accuracy of Masimo SET Pulse Oximetry Enables Monitoring on General
Care Floors
At the heart of Masimo Patient SafetyNet is Masimo SET pulse oximetry,
clinically proven in more than 100 independent and objective studies to
provide the most trustworthy SpO2 and pulse rate measurements, even under the
most difficult clinical conditions of patient motion and low peripheral
perfusion. Previous attempts at developing general care floor monitoring
systems were unsuccessful because the high volume of false pulse oximetry
alarms generated by conventional pulse oximetry led systems to provide false
alarms so often that clinicians ultimately ignored all alarms. Masimo SET
reduced false alarms by over 90% and improved detection of true alarms to over
97%, delivering accurate and reliable alarms and alerts that can be trusted to
reflect a patient's true oxygenation status. This accuracy and reliability
enables clinicians on general care floors to maximize their efficiency and
increase patient safety by responding with confidence to alarms knowing they
represent real clinical events, without being burdened by false alarms.
"The clinical realities of today's general care floors have changed-most
notably due to the increased risk of sentinel events resulting from aggressive
post-operative pain management, an increasing number of patients at risk for
Obstructive Sleep Apnea (OSA) and increased co-morbidities at admission. These
and other issues fundamentally challenge the way in which care is delivered,"
explained Masimo Chairman and CEO Joe E. Kiani. "The combination of these
patient care challenges with the decrease in nurse-to-patient ratios has
resulted in increased populations of higher acuity patients on general care
floors-prompting industry standards bodies to drive a new standard of care
that calls for continuous monitoring of patient oxygen levels with pulse
oximetry, with clinically meaningful alarms sent to appropriate caregivers.
Masimo Patient SafetyNet helps clinicians meet these emerging care standards."
Masimo Rainbow SET Platform Enables Clinicians to Upgrade to New Features
and Measurements
In addition to Masimo Patient SafetyNet, the company will be showcasing
the Masimo Rainbow SET Platform, an innovative, upgradeable multi-functional
technology platform enabling noninvasive, continuous blood constituent and
functional hemodynamic monitoring. The Masimo Rainbow SET Platform allows
clinicians to choose the features and measurements needed to meet their
specific clinical requirements, and then upgrade to additional functionality
whenever they choose. Masimo Rainbow devices come standard with "gold
standard" Masimo SET pulse oximetry, providing accurate and reliable SpO2,
pulse rate and perfusion index measurements, even in the most difficult
clinical conditions. In addition, clinicians can choose to upgrade to
additional measurements including continuous noninvasive carbon monoxide
(SpCO) and methemoglobin (SpMet) monitoring and Pleth Variability Index (PVI)
simply by purchasing field-installed software upgrades whenever they need
them.
When using Masimo Rainbow SET technology, clinicians can more accurately
determine their patients' true oxygenation status by measuring levels of SpMet
and SpCO in the blood, two potentially fatal dyshemoglobins proven to increase
morbidity and mortality in a broad range of clinical settings.
By continuously, noninvasively and accurately determining levels of SpMet,
clinicians can accurately determine if drugs they are administering are
causing methemoglobinemia. The drugs that have been shown to contribute to
methemoglobinemia include Benzocaine, Cetacaine and Prilocaine, Celecoxib,
Dapsone, EMLA Creams, Flutamide, Nitrates, Nitric Oxide, Nitroglycerin, Sodium
Nitroprusside, Sodium Nitrate and Sulfonamides.
In a surgical setting, continuous monitoring of SpCO can allow clinicians
to detect elevated levels of carboxyhemoglobin that can be caused by
everything from desiccated soda lime ("Monday Morning Phenomena") or other
poisons during surgery to smokers reporting for surgery with high SpCO values.
Increased SpCO compromises healing and may lead to death, and smokers with
residual elevated COHb at the time of anesthesia are at cardiac ischemic risk.
Also for the first time at the ASA, Masimo will be showing its latest
Rainbow measurement, Pleth Variability Index, or PVI. The ability to
noninvasively measure and trend PVI, a continuous noninvasive quantified
measurement of changes in the perfusion index that could be indicative of
blood volume status, provides additional indicators of a patient's physiologic
condition, including the patient's level of hydration. This allows for more
precise, timely diagnosis and better treatment decisions that lead to improved
patient outcomes.
"At Masimo, we are wholly dedicated and committed to developing products
and technologies that enable clinicians to deliver the best possible care and
to increase the safety of their patients," Mr. Kiani added. "Since our
beginnings nearly 20 years ago, we have been focused on improving patient
outcomes and reducing the cost of care by bringing noninvasive monitoring to
new sites and new applications. Masimo Patient SafetyNet and the Masimo
Rainbow SET platform are clear examples of this on-going commitment."
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Read-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET, and with it virtually eliminated false alarms
and increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies have confirmed that Masimo SET
technology allows clinicians to accurately monitor blood oxygen saturation in
critical care situations. Our Masimo SET platform has significantly addressed
many of the previous technology limitations, has substantially contributed to
improved patient outcomes and has been referred to by several industry sources
as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo
Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively
monitors the level of carbon monoxide and methemoglobin in the blood, allowing
early detection and treatment of potentially life-threatening conditions.
Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and
Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications." Additional information about Masimo and its products may be
found at http://www.masimo.com.
Contact:
Tom McCall
Masimo Corporation
949-297-7075
Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57,
APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications are registered trademarks of Masimo
Corp. ARM, Acoustic Respiratory Monitoring, BiFi, Rainbow, Patient SafetyNet,
SpCO, SpMet, SpHb and
SOURCE Masimo